Shares of Proteostasis Therapeutics Inc. (NASDAQ:PTI) have been given a consensus recommendation of “Buy” by the six research firms that are covering the company. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $17.00.

PTI has been the subject of a number of research reports. Zacks Investment Research downgraded shares of Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, September 15th. Leerink Swann reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Proteostasis Therapeutics in a report on Friday, August 12th.

In other news, major shareholder Enterprise Associates 12 New bought 461,538 shares of the stock in a transaction on Wednesday, September 14th. The shares were acquired at an average cost of $13.00 per share, for a total transaction of $5,999,994.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Franklin M. Berger bought 69,230 shares of the stock in a transaction on Wednesday, September 14th. The stock was purchased at an average price of $13.00 per share, for a total transaction of $899,990.00. Following the completion of the purchase, the director now directly owns 166,162 shares in the company, valued at $2,160,106. The disclosure for this purchase can be found here. 29.50% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of PTI. Cormorant Asset Management LLC purchased a new stake in Proteostasis Therapeutics during the first quarter valued at about $16,644,000. Franklin Resources Inc. purchased a new stake in Proteostasis Therapeutics during the second quarter valued at about $7,581,000. Vanguard Group Inc. purchased a new stake in Proteostasis Therapeutics during the second quarter valued at about $2,558,000. BlackRock Fund Advisors boosted its stake in Proteostasis Therapeutics by 1,124.5% in the second quarter. BlackRock Fund Advisors now owns 164,771 shares of the company’s stock valued at $1,999,000 after buying an additional 151,315 shares in the last quarter. Finally, Opaleye Management Inc. purchased a new stake in Proteostasis Therapeutics during the second quarter valued at about $1,274,000. Institutional investors and hedge funds own 40.02% of the company’s stock.

Shares of Proteostasis Therapeutics (NASDAQ:PTI) remained flat at $14.95 on Thursday. 82,682 shares of the company were exchanged. Proteostasis Therapeutics has a 12 month low of $5.27 and a 12 month high of $20.63. The company has a 50 day moving average price of $14.35 and a 200-day moving average price of $13.15. The stock’s market capitalization is $286.79 million.

Proteostasis Therapeutics (NASDAQ:PTI) last released its earnings results on Monday, August 15th. The company reported ($0.47) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.41) by $0.06. Equities research analysts expect that Proteostasis Therapeutics will post ($2.22) earnings per share for the current fiscal year.

About Proteostasis Therapeutics

Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.

5 Day Chart for NASDAQ:PTI

Receive News & Stock Ratings for Proteostasis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics Inc. and related stocks with our FREE daily email newsletter.